These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Therapeutic options for hormone-refractory prostate cancer in 2007. Hadaschik BA; Gleave ME Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a strategic target for prostate cancer therapy. Li Y; Cozzi PJ Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for advanced prostate cancer: Looking through new lenses. Vogiatzi P; Cassone M; Claudio L; Claudio PP Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279 [TBL] [Abstract][Full Text] [Related]
7. Management of the spectrum of hormone refractory prostate cancer. Clarke NW Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118 [TBL] [Abstract][Full Text] [Related]
13. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? Strother JM; Beer TM; Dreicer R Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961 [TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. Priolo C; Oh WK; Loda M IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896 [TBL] [Abstract][Full Text] [Related]
15. New molecular targets in advanced prostate cancer. Dawson NA Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for prostate cancer - recent progress in clinical trials. Kipp RT; McNeel DG Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921 [TBL] [Abstract][Full Text] [Related]
17. Role of targeted therapy in the treatment of advanced prostate cancer. Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. Motadi LR; Misso NL; Dlamini Z; Bhoola KD Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Ryan CJ; Lin AM; Small EJ Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]